share_log

Canaccord Genuity Maintains Buy on Health Catalyst, Lowers Price Target to $11

Benzinga ·  Feb 23 22:44

Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $12 to $11.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment